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Disturbed sleep was recently proposed as a novel risk 
factor for type 2 diabetes mellitus (T2DM). Experimental 
restriction of sleep to 4 hours per night for 6 nights result-
ed in impaired glucose tolerance in healthy young adults 
[1]. Because diabetes carries a high risk of cardiovascular 
mortality, the impact of sleep restriction on glucose regu-
lation suggests a mechanism linking short sleep time and 
increased mortality.
The term sleep-disordered breathing (SDB) encompass-
es a range of breathing abnormalities that occur during 
sleep. These include obstructive sleep apnea (OSA), central 
sleep apnea, and periodic breathing. SDB may be more 
common in people with T2DM. Some risk factors for dia-
betes, including obesity, visceral adiposity, and advancing 
age are also associated with SDB. Evidence from a grow-
ing body of research suggests that SDB is associated with 
adverse cardiovascular disease (CVD) risk factors and out-
comes including hypertension and myocardial infarction. 
Similarly, CVD risk is substantially elevated among people 
with diabetes. Since diabetes and SDB not only share im-
portant risk factors, but may also be associated with CVD, 
the two conditions may be related to one another [2-5]. 
Recent research has demonstrated the likelihood of a 
relationship between T2DM and OSA, the most common 
form of SDB. The International Diabetes Federation (IDF) 
[6] consensus statement on sleep apnea and T2DM raises 
awareness of the association between the two conditions, 
which has significant implications on public health and on 
the lives of individuals.
According to the IDF, estimates suggest that up to 40% 
of people with OSA have diabetes [3,6], but the incidence 
of new cases of diabetes in people with OSA is not known. 
In people who have diabetes, the prevalence of OSA may 
be up to 23%, and the prevalence of some form of SDB may 
be as high as 58%. Overweight and obesity may play a role, 
but some recent studies have shown that the association 
between SDB and diabetes is independent of overweight/
obesity. OSA may affect glycemic control in people with 
T2DM, and it is associated with a range of cardiovascular 
complications such as hypertension, stroke, and heart fail-
ure. 
Although early studies indicated a possible causal as-
sociation between the presence of OSA and the develop-
ment of T2DM, several of these studies had significant 
limitations including small sample size, highly selected 
population, inadequate adjustment for confounders, and 
use of surrogate measures such as snoring to assess OSA. 
The Wisconsin Sleep Cohort Study showed a significant 
cross-sectional association between OSA and T2DM for all 
degrees of OSA, which was preserved in participants with 
Correspondence to Won-Young Lee, M.D.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 
Pyeong-dong, Jongno-gu, Seoul 110-746, Korea
Tel: 82-2-2001-1543, Fax: 82-2-2001-1588, E mail: drlwy@hanmail.net
See Article on Page 277-284Seo MH and Lee wy. Sleep disorder in T2DM     275
http://dx.doi.org/10.3904/kjim.2011.26.3.274  http://www.kjim.or.kr
moderate to severe OSA after adjustment for obesity (odds 
ratio, 2.3) [7]. However, the longitudinal data from the 
same study showed that after adjusting for obesity, OSA 
at baseline was not a significant predictor for the develop-
ment of diabetes over 4 years.
In this issue, Shim et al. [8] reported that sleep disorder 
(SD) was prevalent in Korean patients with T2DM and that 
OSA could aggravate the risk of cardiovascular disease. 
They enrolled 784 patients with T2DM and measured 
sleep quality using the self-administered Pittsburgh Sleep 
Quality Index and determined the risk of OSA using the 
Berlin Questionnaire. The findings from this study are 
important because few studies have investigated the as-
sociation between sleep quality and the risk of OSA, par-
ticularly in Asians. Among the patients, 38.4% had poor 
sleep quality and 15.8% were at high risk for OSA. The 
frequency of risk for OSA was higher in patients who were 
obese compared to nonobese patients, and the logistic 
regression analysis revealed male gender and body mass 
index as independent predictors of risk for OSA. 
OSA is common in patients with T2DM, and identify-
ing the mechanisms that underlie this condition and de-
termining the effective treatment options are important. 
Laboratory studies in healthy subjects have shown that 
low cerebral glucose utilization, elevated sympathetic ac-
tivity, high evening cortisol levels, alterations in growth 
hormone release, and elevated markers of inflammation 
mediate the adverse effects of reduced sleep duration and 
quality on glucose metabolism.
Several strategies for the management of SD and car-
diovascular risk factors in T2DM exist. First, weight loss 
has been shown to be associated with improvements in 
the apnea-hypopnea index. Thus, weight loss is a primary 
treatment strategy for OSA in patient who are overweight 
or obese. Second, many studies have investigated whether 
treatment of OSA with continuous positive airway pres-
sure (CPAP) improves glucose metabolism and glycemic 
control. The results, however, of studies on OSA treatment 
in patients with T2DM have been equivocal. Harsch et al. 
[9] reported that CPAP produced a significant improve-
ment in insulin sensitivity after 3 months, but had no 
effect on HbA1c. Milleron et al. [10] and Marin et al. [11] 
reported that treatment of OSA with CPAP affected a 
range of cardiovascular measures, and Mansfield et al. [12] 
showed that CPAP treatment reduced ventricular ectopy 
and improved cardiovascular outcomes in patients with 
heart failure. However, the argument that CPAP treatment 
significantly reduces insulin resistance and HbA1c still 
persists. 
This editorial has addressed the complex relationship 
between SD and T2DM and discussed the various mecha-
nisms linking these two conditions. Despite the availabil-
ity of diagnostic measures and effective treatment, many 
patients with SDB remain undiagnosed. Thus, SD contin-
ues to be a significant health risk for affected individuals 
and the general public. Awareness and timely initiation of 
an effective treatment may prevent potential deleterious 
cardiovascular effects of SD in patients with T2DM.
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